Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scripps Research Institute

www.scripps.edu

Latest From Scripps Research Institute

Equillium Will Study In-Licensed Itolizumab In Three Indications In 2019

Emerging Company Profile: Equillium in-licensed the CD6 inhibitor EQ001 – Biocon's Alzumab (itolizumab), approved in India for psoriasis – and will begin clinical trials for three autoimmune disease indications this year; a Phase Ib/II aGvHD study is under way.

Business Strategies Immune Disorders

BlackThorn Raises $76m To Personalize Medicines For Neurobehavioral Disorders

BlackThorn's series B round will fund the use of AI and machine learning via its PathFinder platform and academic collaborations for the development of targeted therapies.

Financing Neurology

Venture Funding Deals: CNS Plays Are Attracting Investment

Polyneuron, Synerkine, Harmony, EIP Pharma and AITI Life Sciences all raised cash in recent weeks to tackle various conditions involving the nervous system. More recent venture funding deals... 

Financing StartUps and SMEs

Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try

Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.

Financing StartUps and SMEs
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register